
EquitySector - HealthcareVery High Risk
Regular
NAV (11-Dec-25)
Returns (Since Inception)
Fund Size
₹339 Cr
Expense Ratio
2.37%
ISIN
INF0QA701987
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
27 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-3.12%
— (Cat Avg.)
| Equity | ₹322.33 Cr | 95.21% |
| Debt | ₹0.79 Cr | 0.23% |
| Others | ₹15.44 Cr | 4.56% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Divi's Laboratories Ltd | Equity | ₹28.46 Cr | 8.41% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹27.88 Cr | 8.24% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹20.07 Cr | 5.93% |
| Aurobindo Pharma Ltd | Equity | ₹18.75 Cr | 5.54% |
| Cipla Ltd | Equity | ₹17.14 Cr | 5.06% |
| Piramal Pharma Ltd | Equity | ₹14.89 Cr | 4.40% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹14.7 Cr | 4.34% |
| Neuland Laboratories Ltd | Equity | ₹14.42 Cr | 4.26% |
| Biocon Ltd | Equity | ₹13.53 Cr | 4.00% |
| Emcure Pharmaceuticals Ltd | Equity | ₹11.6 Cr | 3.43% |
| Fortis Healthcare Ltd | Equity | ₹11.05 Cr | 3.26% |
| Rubicon Research Ltd | Equity | ₹8.37 Cr | 2.47% |
| Lupin Ltd | Equity | ₹7.55 Cr | 2.23% |
| Ipca Laboratories Ltd | Equity | ₹7.34 Cr | 2.17% |
| Future on Aurobindo Pharma Ltd | Equity - Future | ₹7.24 Cr | 2.14% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹6.94 Cr | 2.05% |
| Pfizer Ltd | Equity | ₹6.62 Cr | 1.96% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹6.46 Cr | 1.91% |
| Shaily Engineering Plastics Ltd | Equity | ₹6.46 Cr | 1.91% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹6.16 Cr | 1.82% |
| Zydus Wellness Ltd | Equity | ₹5.94 Cr | 1.75% |
| Godrej Consumer Products Ltd | Equity | ₹5.73 Cr | 1.69% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹5.38 Cr | 1.59% |
| Dr. Lal PathLabs Ltd | Equity | ₹5.38 Cr | 1.59% |
| Abbott India Ltd | Equity | ₹5.23 Cr | 1.54% |
| Bajaj Finserv Money Market Dir Gr | Mutual Fund - Open End | ₹5.04 Cr | 1.49% |
| Medi Assist Healthcare Services Ltd | Equity | ₹4.78 Cr | 1.41% |
| Medplus Health Services Ltd | Equity | ₹4.18 Cr | 1.23% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹4.07 Cr | 1.20% |
| Rainbow Childrens Medicare Ltd | Equity | ₹3.99 Cr | 1.18% |
| Hindustan Unilever Ltd | Equity | ₹3.84 Cr | 1.14% |
| Torrent Pharmaceuticals Ltd | Equity | ₹3.84 Cr | 1.13% |
| Jubilant Pharmova Ltd | Equity | ₹3.81 Cr | 1.13% |
| Alembic Pharmaceuticals Ltd | Equity | ₹3.62 Cr | 1.07% |
| Syngene International Ltd | Equity | ₹3.57 Cr | 1.06% |
| Tata Consumer Products Ltd | Equity | ₹3.52 Cr | 1.04% |
| Net Receivables / (Payables) | Cash | ₹-3.51 Cr | 1.04% |
| Emami Ltd | Equity | ₹3.44 Cr | 1.02% |
| Mankind Pharma Ltd | Equity | ₹3.27 Cr | 0.97% |
| AstraZeneca Pharma India Ltd | Equity | ₹2.95 Cr | 0.87% |
| Eternal Ltd | Equity | ₹2.63 Cr | 0.78% |
| Marico Ltd | Equity | ₹2.27 Cr | 0.67% |
Large Cap Stocks
37.81%
Mid Cap Stocks
22.95%
Small Cap Stocks
31.98%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹281.28 Cr | 83.08% |
| Consumer Defensive | ₹24.73 Cr | 7.30% |
| Basic Materials | ₹6.46 Cr | 1.91% |
| Consumer Cyclical | ₹2.63 Cr | 0.78% |
Standard Deviation
This fund
--
Cat. avg.
16.00%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better

Since December 2024

Since December 2024

Since December 2024
ISIN INF0QA701987 | Expense Ratio 2.37% | Exit Load 1.00% | Fund Size ₹339 Cr | Age 11 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹31,759 Cr
Address
8th floor, E-Core,Solitaire Business Hub (formerly Marvel Edge), Viman Nagar 411014
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Regular
NAV (11-Dec-25)
Returns (Since Inception)
Fund Size
₹339 Cr
Expense Ratio
2.37%
ISIN
INF0QA701987
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
27 Dec 2024
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
Since Inception
-3.12%
— (Cat Avg.)
| Equity | ₹322.33 Cr | 95.21% |
| Debt | ₹0.79 Cr | 0.23% |
| Others | ₹15.44 Cr | 4.56% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Divi's Laboratories Ltd | Equity | ₹28.46 Cr | 8.41% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹27.88 Cr | 8.24% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹20.07 Cr | 5.93% |
| Aurobindo Pharma Ltd | Equity | ₹18.75 Cr | 5.54% |
| Cipla Ltd | Equity | ₹17.14 Cr | 5.06% |
| Piramal Pharma Ltd | Equity | ₹14.89 Cr | 4.40% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹14.7 Cr | 4.34% |
| Neuland Laboratories Ltd | Equity | ₹14.42 Cr | 4.26% |
| Biocon Ltd | Equity | ₹13.53 Cr | 4.00% |
| Emcure Pharmaceuticals Ltd | Equity | ₹11.6 Cr | 3.43% |
| Fortis Healthcare Ltd | Equity | ₹11.05 Cr | 3.26% |
| Rubicon Research Ltd | Equity | ₹8.37 Cr | 2.47% |
| Lupin Ltd | Equity | ₹7.55 Cr | 2.23% |
| Ipca Laboratories Ltd | Equity | ₹7.34 Cr | 2.17% |
| Future on Aurobindo Pharma Ltd | Equity - Future | ₹7.24 Cr | 2.14% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹6.94 Cr | 2.05% |
| Pfizer Ltd | Equity | ₹6.62 Cr | 1.96% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹6.46 Cr | 1.91% |
| Shaily Engineering Plastics Ltd | Equity | ₹6.46 Cr | 1.91% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹6.16 Cr | 1.82% |
| Zydus Wellness Ltd | Equity | ₹5.94 Cr | 1.75% |
| Godrej Consumer Products Ltd | Equity | ₹5.73 Cr | 1.69% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹5.38 Cr | 1.59% |
| Dr. Lal PathLabs Ltd | Equity | ₹5.38 Cr | 1.59% |
| Abbott India Ltd | Equity | ₹5.23 Cr | 1.54% |
| Bajaj Finserv Money Market Dir Gr | Mutual Fund - Open End | ₹5.04 Cr | 1.49% |
| Medi Assist Healthcare Services Ltd | Equity | ₹4.78 Cr | 1.41% |
| Medplus Health Services Ltd | Equity | ₹4.18 Cr | 1.23% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹4.07 Cr | 1.20% |
| Rainbow Childrens Medicare Ltd | Equity | ₹3.99 Cr | 1.18% |
| Hindustan Unilever Ltd | Equity | ₹3.84 Cr | 1.14% |
| Torrent Pharmaceuticals Ltd | Equity | ₹3.84 Cr | 1.13% |
| Jubilant Pharmova Ltd | Equity | ₹3.81 Cr | 1.13% |
| Alembic Pharmaceuticals Ltd | Equity | ₹3.62 Cr | 1.07% |
| Syngene International Ltd | Equity | ₹3.57 Cr | 1.06% |
| Tata Consumer Products Ltd | Equity | ₹3.52 Cr | 1.04% |
| Net Receivables / (Payables) | Cash | ₹-3.51 Cr | 1.04% |
| Emami Ltd | Equity | ₹3.44 Cr | 1.02% |
| Mankind Pharma Ltd | Equity | ₹3.27 Cr | 0.97% |
| AstraZeneca Pharma India Ltd | Equity | ₹2.95 Cr | 0.87% |
| Eternal Ltd | Equity | ₹2.63 Cr | 0.78% |
| Marico Ltd | Equity | ₹2.27 Cr | 0.67% |
Large Cap Stocks
37.81%
Mid Cap Stocks
22.95%
Small Cap Stocks
31.98%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹281.28 Cr | 83.08% |
| Consumer Defensive | ₹24.73 Cr | 7.30% |
| Basic Materials | ₹6.46 Cr | 1.91% |
| Consumer Cyclical | ₹2.63 Cr | 0.78% |
Standard Deviation
This fund
--
Cat. avg.
16.00%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better

Since December 2024

Since December 2024

Since December 2024
ISIN INF0QA701987 | Expense Ratio 2.37% | Exit Load 1.00% | Fund Size ₹339 Cr | Age 11 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹31,759 Cr
Address
8th floor, E-Core,Solitaire Business Hub (formerly Marvel Edge), Viman Nagar 411014
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments